This document reflects the need for a guideline on the evaluation of the safety and efficacy of thrombopoetin receptor agonists fin the treatment of chronic immune (idiopathic) thrombocytopenic purpura.

Keywords: Chronic immune idiopathic thrombocytopenic purpura, ITP, thrombopoeting agonists

Current effective version

Share this page